Tech Company Financing Transactions
Nucleome Therapeutics Funding Round
Nucleome Therapeutics secured a $42.2 million Series A funding round on 10/19/2022. Investors included M Ventures, British Patient Capital and Johnson & Johnson Innovation.
Transaction Overview
Company Name
Announced On
10/19/2022
Transaction Type
Venture Equity
Amount
$42,220,000
Round
Series A
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Suite C, Second Floor, Schrodinger Building, Oxford Science
Oxford, OX4 4GE
UK
Oxford, OX4 4GE
UK
Phone
Undisclosed
Website
Email Address
Overview
Nucleome has the unique ability to discover and validate first-in-class targets through genetics in the dark genome. Understanding the role of these genetic variants has been a long-standing challenge, hindering the translation of the human genome into useful drug discovery insights. The dark matter, or non-coding regions of DNA, makes up around 98% of our DNA and we now know that 90% of disease associated genetic variations originate here. Instead of coding for proteins, this dark genome has a regulatory role, it controls gene expression. It acts like an instruction processor, turning genes on and off at the right time and levels. This enables our genetic code to be translated into the hundreds of cell types that exist.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Danuta Jeziorska
Chief Financial Officer
Phil Boyd
VP - Operations
Dina Anderson
Browse more venture capital transactions:
Prev: 10/19/2022: H2 Green Steel venture capital transaction
Next: 10/19/2022: Sensat venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs